An N-(9H-carbazole-3-yl)benzamide derivative and its application
By designing N-(9H-carbazole-3-yl)benzamide derivatives, the problem of insufficient number of HSF1 inhibitors was solved, achieving potent inhibition of heat shock factor 1 and exhibiting significant anti-cancer effects.
Patent Information
- Application Number
- CN202510627847.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-15
- Publication Date
- 2026-11-17
AI Technical Summary
There are few existing HSF1 inhibitors, which are insufficient to effectively inhibit the activity of heat shock factor 1, thus affecting the proliferation and metastasis of tumor cells.
Develop an N-(9H-carbazole-3-yl)benzamide derivative that, through specific structural design, can potently inhibit the activity of HSF1, for use in the preparation of heat shock protein inhibitors and drugs for treating related diseases.
It significantly inhibits the growth of various cancer cell lines, providing a broad application space for anti-cancer drugs and filling the gap in the insufficient activity of existing HSF1 inhibitors.
Smart Images

Figure CN123106513A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical technology, and more specifically, to an N-(9H-carbazole-3-yl)benzamide derivative and its applications. Background Technology
[0002] Heat shock factor 1 (HSF1) is a major regulator of the heat shock response. HSF1 promotes the correct folding, maintenance, or degradation of proteins by regulating the expression of molecular chaperones such as heat shock proteins (HSPs), thereby maintaining protein homeostasis and helping cells survive under rapid stress.
[0003] In tumor cells, in addition to regulating the heat shock response, HSF1 also promotes the proliferation, invasion and metastasis of tumor cells by controlling gene expression in the cell cycle, inhibiting apoptosis and maintaining the tumor microenvironment. HSF1 has become a biomarker for a variety of malignant tumors and is regarded as a promising anti-tumor target.
[0004] Currently, there are publicly available direct HSF1 inhibitors, including KRIBB11, IHSF1115, and DTHIB, but the number is still relatively small. Exploring more HSF1 inhibitors has become an urgent technical problem to be solved. Summary of the Invention
[0005] To address the aforementioned technical problems, the present invention aims to provide an N-(9H-carbazole-3-yl)benzamide derivative. The N-(9H-carbazole-3-yl)benzamide derivative provided by the present invention exhibits a strong inhibitory effect on heat shock factor 1 and a significant inhibitory effect on various cancer cell lines.
[0006] Another object of the present invention is to provide the use of the N-(9H-carbazole-3-yl)benzamide derivative in the preparation of heat shock protein inhibitors.
[0007] Another object of the present invention is to provide the use of the N-(9H-carbazole-3-yl)benzamide derivative in the preparation of medicaments for the prevention and / or treatment of heat shock factor 1-mediated diseases.
[0008] Another object of the present invention is to provide a heat shock protein inhibitor.
[0009] The above-mentioned objective of the present invention is achieved by the following solution:
[0010] This invention provides an N-(9H-carbazole-3-yl)benzamide derivative having the structure shown in formula (I):
[0011]
[0012] Among them, R1 is selected from halogen, C 1~8 Alkoxy; the C 1~8 The alkoxy group is either unsubstituted or substituted with one or more -NR5R6 groups;
[0013] R2 is selected from nitro, C 3~8 cycloalkyl, C 3~8 Heterocyclic groups;
[0014] R3 is selected from hydrogen, C 1~8 Alkyl, C 1~8 alkoxycarbonyl;
[0015] R4 is selected from C 3~8 cycloalkyl, C 3~8 Heterocyclic group, C 2~8 alkenyl, C 1~8 Alkyl; the C 2~8 alkenyl, C 1~8 Alkyl groups that are unsubstituted or via one or more amino groups, C 3~12 Cycloalkylamino, aryl, heteroaryl, C 3~8 Substitution of heterocyclic groups;
[0016] R5 and R6 are each independently selected from hydrogen and C. 1~8 Alkyl groups; or R5, R6, and the nitrogen atom attached to them to form C 3~8 Heterocyclic group.
[0017] Preferably, R1 is selected from fluorine, chlorine, bromine, C 2~6 Alkoxy; the C 2~6 The alkoxy group is either unsubstituted or substituted with one or more -NR5R6 groups;
[0018] R2 is selected from nitro, C 3~6 cycloalkyl, C 3~6 Heterocyclic groups;
[0019] R3 is selected from hydrogen, C 1~4 Alkyl, C 1~4 alkoxycarbonyl;
[0020] R4 is selected from C 4~6 cycloalkyl, C 4~6 Heterocyclic group, C 2~6 alkenyl, C 1~4 Alkyl; the C 2~6 alkenyl, C 1~4 Alkyl groups that are unsubstituted or via one or more amino groups, C 3~12 Cycloalkylamino, C 5~6 Aryl, C 5~6 heteroaryl, C4~6 Substitution of heterocyclic groups;
[0021] R5 and R6 are each independently selected from hydrogen and C. 1~4 Alkyl groups; or R5, R6, and the nitrogen atom attached to them to form C 4~6 Heterocyclic group.
[0022] Preferably, R1 is selected from chlorine, C 3~5 Alkoxy; the C 3~5 The alkoxy group is either unsubstituted or substituted with one or more -NR5R6 groups;
[0023] R2 is selected from nitro, C 3~6 cycloalkyl, C 3~6 Heterocyclic groups;
[0024] R3 is selected from hydrogen, C 1~4 Alkyl, C 1~4 alkoxycarbonyl;
[0025] R4 is selected from pyranyl, tetrahydropyrrolyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, piperazine, dioxane, C 2~4 alkenyl, C 1~3 Alkyl; the C 2~4 alkenyl, C 1~3 The alkyl group is either unsubstituted or substituted with one or more phenyl, pyranyl, tetrahydropyrrolyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, piperazine, or adamantylamino groups;
[0026] R5 and R6 are each independently selected from C 1~3 Alkyl groups; or nitrogen atoms attached to R5 and R6 to form pyranyl, tetrahydropyrroleyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, piperazineyl, or dioxaneyl.
[0027] Preferably, R1 is selected from chlorine, styrylformamido, 2-morpholinoacetamido, 2-adamantaneaminoacetamido, 3-dimethylaminopropoxy, 4-(dimethylamino)butoxy, 5-(dimethylamino)pentoxy, 3-(pyrrolidone-1-yl)propoxy, 4-(pyrrolidone-1-yl)butoxy, 5-(pyrrolidone-1-yl)pentoxy, 3-(piperidin-1-yl)propoxy, 4-(piperidin-1-yl)butoxy, 5-(piperidin-1-yl)pentoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, and 5-morpholinopentoxy.
[0028] R2 is selected from nitro or cyclopropyl;
[0029] R3 is selected from hydrogen, ethyl, or tert-butoxycarbonyl.
[0030] Preferably, the N-(9H-carbazole-3-yl)benzamide derivative has any of the following structures:
[0031]
[0032]
[0033] Furthermore, the present invention claims protection for the use of the N-(9H-carbazole-3-yl)benzamide derivative in the preparation of heat shock protein inhibitors.
[0034] Furthermore, the present invention seeks protection for the use of the N-(9H-carbazole-3-yl)benzamide derivative in the preparation of medicaments for the prevention and / or treatment of heat shock factor 1-mediated diseases.
[0035] Preferably, the relevant disease is one or more of colon adenocarcinoma, osteosarcoma, colon cancer, and prostate cancer.
[0036] Preferably, the heat shock factor 1 induces related diseases by mediating heat shock protein HSP90 or heat shock protein HSP70.
[0037] Furthermore, the present invention claims protection for a heat shock protein inhibitor comprising the N-(9H-carbazole-3-yl)benzamide derivative; and pharmaceutically acceptable excipients.
[0038] Compared with the prior art, the present invention has the following beneficial effects:
[0039] This invention provides an N-(9H-carbazole-3-yl)benzamide derivative, which has a strong inhibitory effect on heat shock factor 1 and a significant inhibitory effect on various cancers. It has broad application potential in anticancer drugs and can fill the gap in the insufficient activity of current HSF1 direct inhibitors. Attached Figure Description
[0040] Figure 1 This is a schematic diagram illustrating the inhibition of HSF1 activity by the compound. Detailed Implementation
[0041] The present invention will be further described in detail below with reference to specific embodiments. These embodiments are only used to explain the present invention and are not intended to limit the scope of the present invention. Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods; the materials and reagents used are commercially available unless otherwise specified.
[0042] The term "halogen" refers to fluorine, chlorine, bromine, and iodine. The term "halogen" preceding the group name indicates that the group is partially or completely halogenated, that is, replaced by F, Cl, Br, or I in any combination.
[0043] The term "alkyl" refers to a saturated straight-chain or branched hydrocarbon group. The alkyl group is preferably C10. 1~8 Alkyl groups, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or similar groups.
[0044] The term "alkyl" refers to a saturated straight-chain or branched hydrocarbon group. The alkyl group is preferably C10. 2~8 Alkyl groups, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or similar groups.
[0045] The term "cycloalkyl" refers to a saturated or partially unsaturated cycloalkyl group, including monocyclic or polycyclic groups. Unless otherwise specified, a cycloalkyl group can have 3 to 12 carbon atoms. For example, a cycloalkyl group can be a monocyclic group with 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-3-enyl, cyclohexene, 1-cyclohex-1-enyl, cyclohexadiene, cycloheptene, cyclooctene, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, or similar groups. A cycloalkyl group can also be a bicyclic group with 6 to 10 carbon atoms, such as bicyclic [4,5], [5,5], [5,6] and [6,6] ring systems, or similar groups selected from bicyclic [2.2.1]heptane, bicyclic [2.2.2]octane, or adamantyl. The cycloalkyl group can be saturated or have at least one double bond, but is not fully conjugated and is not aromatic.
[0046] The term "heterocyclic group" refers to a ring selected from 3- to 8-membered monocyclic or bicyclic saturated or partially unsaturated rings containing at least one carbon atom in addition to 1, 2, 3, or 4 heteroatoms selected from O, S, or N. The heterocycle may be saturated or contain at least one double bond. The heterocyclic group can be attached to the rest of the molecule via a carbon atom or a heteroatom. Examples of heterocyclic groups include, but are not limited to, pyranyl, tetrahydropyrroleyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, and piperazineyl.
[0047] The term "alkoxy group" refers to a saturated straight-chain or branched group connected to the rest of the molecule by an oxygen atom, usually denoted by RO-, where R is an alkyl group. Unless otherwise stated, the alkoxy group is an alkoxy group having 1 to 8 carbon atoms, examples of which include, but are not limited to, methoxy groups.
[0048] The term "aryl" refers to a 5- to 6-membered aromatic ring or a 7- to 12-membered bicyclic system, wherein at least one ring in the bicyclic system is an aromatic ring. For example, (a) 5- to 6-membered aromatic rings include, but are not limited to, phenyl; (b) aryl groups in 7- to 12-membered bicyclic systems, wherein at least one ring is an aromatic ring, such as naphthyl.
[0049] The term "heteroaryl" refers to a 5- to 7-membered aromatic monocyclic ring or an 8- to 12-membered bicyclic ring; it contains 1, 2, 3, or 4 heteroatoms selected from N, O, or S, and the remaining ring atoms are carbon; among them, at least one ring of the 8- to 12-membered bicyclic ring and the 11- to 14-membered bicyclic ring is aromatic, and at least one heteroatom is present in the aromatic ring.
[0050] Example 1: Synthesis of compound KZ1
[0051] 4-Chloro-3-nitrobenzoic acid, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (HATU), and N,N-diisopropylethylamine (DIPEA) were dissolved in an appropriate amount of N,N-dimethylformamide (DMF) in a ratio of 1:1:2. The mixture was stirred at room temperature for 15 min. Separately, a small amount of 3-amino-9-ethylcarbazole was dissolved in a small amount of DMF and added dropwise to the reaction system. The reaction was carried out at room temperature for about 3 h. After the reaction was completed, the reaction solution was extracted three times with ethyl acetate / water. The combined organic phases were washed once with saturated sodium chloride aqueous solution. The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography to obtain a yellow solid, which was compound KZ1.
[0052]
[0053] Compound KZ1
[0054] Yield: 76%; 1 H NMR (500MHz, DMSO-d6) δ10.62(s,1H),8.70(s,1H),8.53(s,1H),8.33(d,J=8.4Hz,1H),8.10(d,J=7.7Hz,1H),8.00(d,J=8.4Hz,1 H),7.76(d,J=8.7Hz,1H),7.62(t,2H),7.47(t,J=7.6Hz,1H),7.20(t,J=7.4Hz,1H),4.45(q,J=7.2Hz,2H),1.32(t,J=7.1Hz,3H). 13C NMR (126MHz, DMSO-d6) δ162.33,147.52,140.18,136.92,135.27,135.24,135.24,132.94,132.17,130.36,12 8.08,126.12,124.91,122.16,121.99,120.40,118.93,113.10,109.43,109.20,37.19,13.87.ESI-HRMS[M+H] + m / z = 394.0953.
[0055] Example 2: Synthesis of compound KZ2
[0056] (1) Synthesis of compound KZ2-1
[0057] The method is the same as in Example 1, except that 4-nitro-3-bromobenzoic acid is used instead of 4-chloro-3-nitrobenzoic acid.
[0058]
[0059] Compound KZ2-1
[0060] Yield: 88%; 1 H NMR(400MHz,Chloroform-d)δ8.40(s,1H),8.29(s,1H),8.09(d,J=7.8Hz,1H),7.96(q,J=8.6Hz,3H),7.62(d,J=8.6Hz, 1H),7.53–7.47(m,1H),7.42(dd,J=8.4,6.0Hz,2H),7.23(d,J=7.3Hz,1H),4.38(q,J=7.2Hz,2H),1.45(t,J=7.2Hz,3H).
[0061] (2) Synthesis of compound KZ2-2
[0062] The raw material KZ2-1 was dissolved in ethanol / water (3:1) with 5 equivalent iron powder and 0.5 equivalent ammonium chloride. The mixture was heated to 95°C and refluxed for 15 min. After the reaction solution cooled to room temperature, it was filtered through diatomaceous earth. The filter residue was washed with dichloromethane. The filtrate was concentrated under reduced pressure and dried to obtain a yellow solid, which was compound KZ2-2. No further purification was required.
[0063]
[0064] Compound KZ2-2
[0065] Yield: 93%; 1H NMR (400MHz, DMSO-d6) δ9.97(s,1H),8.49(d,J=2.0Hz,1H),8.12(d,J=2.1Hz,1H),8.07(d,J=7.7Hz,1H),7.89–7.79(m,1H),7.73(dd,J=8.8,2.1Hz,1 H),7.58(t,J=7.9Hz,2H),7.54–7.39(m,1H),7.18(t,J=7.5Hz,1H),6.86( d,J=8.5Hz,1H),5.94(s,2H),4.43(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).
[0066] (3) Synthesis of compound KZ2-3
[0067] The starting material KZ2-2 was dissolved in toluene / water (10:1) with 1.5 equivalents of cyclopropylboronic acid, 0.1 equivalents of palladium acetate, 0.2 equivalents of tricyclohexylphosphine, and 5 equivalents of potassium phosphate. The mixture was heated to 100°C and reacted overnight under nitrogen protection. After the reaction was complete and the system cooled to room temperature, ethyl acetate and water were added for extraction three times. The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography to obtain a yellow solid, which was compound KZ2-3.
[0068]
[0069] Compound KZ2-3
[0070] Yield: 80%; 1 H NMR (400MHz, DMSO-d6) δ9.82(s,1H),8.47(d,J=2.0Hz,1H),8.07(d,J=7.7Hz,1H),7.73( dd,J=8.8,2.1Hz,1H),7.66(dd,J=8.4,2.2Hz,1H),7.62–7.54(m,3H),7.48–7.42(m,1H), 7.18(t,J=7.4Hz,1H),6.68(d,J=8.3Hz,1H),5.61(s,2H),4.43(q,J=7.1Hz,2H),1.72(d dd,J=13.7,8.4,5.3Hz,1H),1.32(t,J=7.1Hz,3H),0.95–0.89(m,2H),0.64–0.58(m,2H).
[0071] (4) Synthesis of compound KZ2
[0072] The method is the same as in Example 1, except that tetrahydropyran-4-carboxylic acid is used instead of 4-chloro-3-nitrobenzoic acid, and KZ2-3 is used instead of 3-amino-9-ethylcarbazole, to obtain a pale yellow solid, which is compound KZ2.
[0073]
[0074] compound KZ2
[0075] Yield: 78%; 1 H NMR (400MHz, DMSO-d6) δ10.19(s,1H),9.42(s,1H),8.50(s,1H),8.09(d,J=7.7Hz,1H),7.82(dd,J=8.4,1.7Hz,1H),7.75(d d,J=8.7,1.7Hz,1H),7.70(d,J=8.4Hz,1H),7.68–7.63(m,1H),7.60(d,J=8.5Hz,2H),7.45(t,J=7.8Hz,1H),7.19(t,J=7.4 Hz,1H),4.44(q,J=6.9Hz,2H),4.00–3.88(m,2H),3.44–3.35(m,2H),2.78(ddd,J=15.3,10.8,4.1Hz,1H),2.08(ddd,J=11. 3,8.5,5.5Hz,1H),1.74(dtd,J=24.6,12.3,11.5,5.8Hz,4H),1.32(t,J=7.1Hz,3H),1.08–0.95(m,2H),0.79–0.67(m,2H). 13 C NMR(126MHz,DMSO-d6)δ173.71,165.17,140.48,140.45,136.95,135.98,131.63,131.36,126.22,125.78,125.55,124.28,122 .58,122.27,120.98,120.66,119.08,113.47,109.66,109.28,66.92,41.71,37.47,29.48,14.20,11.65,8.07.ESI-HRMS[M+H] + m / z = 482.2438.
[0076] Example 3 Synthesis of compound KZ3
[0077] The method is the same as in Example 1, except that (2E)-2-phenyl-2-acrylic acid is used instead of 4-chloro-3-nitrobenzoic acid, and KZ2-3 is used instead of 3-amino-9-ethylcarbazole to obtain a white solid, which is compound KZ3.
[0078]
[0079] Compound KZ3
[0080] Yield: 67%. 1 H NMR (400MHz, DMSO-d6) δ10.21(s,1H),9.65(s,1H),8.52(s,1H),8.10(d,J=7.8Hz,1H),7. 98(d,J=8.4Hz,1H),7.86(d,J=8.1Hz,1H),7.76(d,J=8.4Hz,1H),7.68(d,J=7.5Hz,3H),7 .60(q,J=8.7,7.3Hz,3H),7.53–7.40(m,4H),7.25–7.10(m,2H),4.45(q,J=6.8,6.2Hz,2H ),2.25–2.09(m,1H),1.33(t,J=6.6Hz,3H),1.06(d,J=7.5Hz,2H),0.79(d,J=3.9Hz,2H). 13 C NMR(126MHz,DMSO-d6)δ165.18,164.47,141.08,140.52,140.46,136.96,135.25,131.48,131.40,130.33,129.50,128.31,126.23,125.90,1 25.46,123.35,122.74,122.59,122.28,120.96,120.67,119.09,113. 45,112.99,109.67,109.30,37.47,14.20,11.62,8.26.ESI-HRMS[M+H] + m / z = 500.2341.
[0081] Example 4: Synthesis of compound KZ4
[0082] (1) Synthesis of compound KZ4-1
[0083] Compound KZ2-3 was dissolved in dichloromethane with 3 equivalents of triethylamine, cooled in an ice bath, and 1.5 equivalents of chloroacetyl chloride were added dropwise. After the reaction was completed, ice water was added to quench the reaction. The mixture was extracted three times with dichloromethane / saturated sodium bicarbonate solution, the organic phases were combined, and the mixture was evaporated to dryness without purification to obtain compound KZ4-1.
[0084]
[0085] Compound KZ4-1
[0086] Yield: 93%; 1 H NMR(400MHz,DMSO-d6)δ10.62(s,1H),10.25(s,1H),8.51(s,1H),8.31(s,1H),8 .08(d,J=7.8Hz,1H),7.93(d,J=8.3Hz,1H),7.84(s,1H),7.76(d,J=8.8Hz,1H),7 .58(t,J=7.6Hz,2H),7.45(t,J=7.7Hz,1H),7.18(t,J=7.5Hz,1H),4.43(d,J=7. 3Hz,2H),1.97(s,2H),1.31(t,J=7.1Hz,3H),1.05(s,2H),0.76(d,J=5.2Hz,2H).
[0087] (2) Synthesis of compound KZ4
[0088] Compound KZ4-1, 3 equivalents of potassium carbonate, and 1 equivalent of morpholine were dissolved in DMF and the mixture was heated to 60°C for reaction. After the reaction was completed, the reaction solution was extracted three times with ethyl acetate / water. The organic phases were combined and then washed once with saturated sodium chloride aqueous solution. The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography to obtain a white solid, which was compound KZ4.
[0089]
[0090] compound KZ4
[0091] Yield: 55%; 1H NMR (400MHz, DMSO-d6) δ10.21(s,1H),10.00(s,1H),8.51(s,1H),8.33(d,J=8.3Hz,1H),8.09(d ,J=7.6Hz,1H),7.92(d,J=8.0Hz,1H),7.86(s,1H),7.76(d,J=8.1Hz,1H),7.60(d,J=8.4Hz,2H) ,7.46(t,J=7.3Hz,1H),7.19(t,J=7.2Hz,1H),4.44(d,J=6.9Hz,2H),3.68(s,4H),3.23(s,2H), 2.61(s,4H),2.03–1.90(m,1H),1.32(t,J=6.7Hz,3H),1.11(d,J=7.2Hz,2H),0.88–0.74(m,2H). 13 C NMR(101MHz,DMSO-d6)δ168.78,167.76–167.67(m),165.02,140.70,140.46,136.95,131.40,131.26,130.15,127.84,127.06,126.2 3,122.59,122.28,120.98,120.66,119.08,113.46,109.67,109.29,66.85,62.68,53.84,37.48,14.20,11.76,6.44.ESI-HRMS[M+H] + m / z = 497.2547.
[0092] Example 5: Synthesis of compound KZ5
[0093] The preparation method is the same as step (2) of Example 4, except that adamantane is used instead of morpholine to obtain a pale yellow solid, which is compound KZ5.
[0094]
[0095] Compound KZ5
[0096] Yield: 73%; 1H NMR (500MHz, DMSO-d6) δ10.61(s,1H),10.18(s,1H),8.50(d,J=1.7Hz,1H),8.42(s,1H),8.09(d,J=7.7Hz,1H ),7.90(dd,J=8.5,1.8Hz,1H),7.85(s,1H),7.75(dd,J=8.8,1.8Hz,1H),7.59(d,J=8.6Hz,2H),7.50–7.41(m ,1H),7.19(t,J=7.3Hz,1H),4.44(q,J=7.0Hz,2H),2.11–1.94(m,4H),1.90(d,J=6.9Hz,1H),1.60(d,J=15.5 Hz,11H),1.32(t,J=7.1Hz,3H),1.24(s,2H),1.13–1.07(m,2H),0.85(t,J=6.9Hz,1H),0.79(q,J=5.5Hz,2H). 13 C NMR(126MHz,DMSO-d6)δ165.08,165.06,140.45,136.93,131.43,130.12,127.88,127.42,127.19,126.22,122.58,122.27,120.97,120.66,1 19.07,118.01,113.49,113.44,109.66,109.28,42.40,37.47,36.55, 29.55,29.30,27.02,22.57,14.42,14.20,11.99,6.53.ESI-HRMS[M+H] + m / z = 561.3236.
[0097] Example 6: Synthesis of compound KZ6
[0098] (1) Synthesis of compound KZ6-1
[0099] The preparation method is the same as the synthesis of compound KZ2-3 in step (3) of Example 2, except that methyl 3-bromo-4-chlorobenzoate is used to replace the raw material KZ2-2, and a white solid is obtained, which is compound KZ6-1.
[0100]
[0101] Compound KZ6-1
[0102] Yield: 72%; 1H NMR(400MHz,Chloroform-d)δ7.75(dd,J=8.3,2.1Hz,1H),7.61(d,J=2.1Hz,1H),7.40(d,J= 8.3Hz,1H),3.89(s,3H),2.20(tt,J=8.5,5.3Hz,1H),1.12–1.00(m,2H),0.80–0.70(m,2H).
[0103] (2) Synthesis of compound KZ6
[0104] KZ6-1 was dissolved in methanol / 1M lithium hydroxide (1:1), and the mixture was heated to 60℃ and reacted for 3 hours. After the reaction was completed, 1M dilute hydrochloric acid was added to adjust the pH to about 2. The reaction solution was evaporated to dryness, and then dissolved in DMF with 1 equivalent of HATU and 2 equivalents of DIPEA. After stirring for 15 minutes, 1 equivalent of 3-amino-9-ethylcarbazole was dissolved in a small amount of DMF and added dropwise to the reaction system. The reaction was carried out at room temperature for about 3 hours. After the reaction was completed, the reaction solution was extracted three times with ethyl acetate / water. The organic phases were combined and washed once with saturated sodium chloride aqueous solution. The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography to obtain a pale yellow solid, which was compound KZ6.
[0105]
[0106] Compound KZ6
[0107] Yield: 69%; 1 H NMR (400MHz, DMSO-d6) δ10.31(s,1H),8.49(d,J=2.0Hz,1H),8.10(d,J=7.7Hz,1H),7 .83(dd,J=8.3,2.2Hz,1H),7.74(dd,J=8.7,2.1Hz,1H),7.64(d,J=2.2Hz,1H),7.63– 7.57(m,3H),7.46(t,J=7.7Hz,1H),7.19(t,J=7.4Hz,1H),4.44(q,J=7.1Hz,2H),2.2 9–2.16(m,1H),1.32(t,J=7.1Hz,3H),1.08(dt,J=8.6,3.2Hz,2H),0.95–0.81(m,2H). 13C NMR (101MHz, DMSO-d6) δ164.17,140.61,140.00,136.93,136.60,134.02,130.61,129.01,126.40,125.80,125. 08,122.08,121.81,120.54,120.21,118.65,113.12,109.22,108.86,37.01,13.72,13.11,8.37.ESI-HRMS[M+H] + m / z = 389.1427.
[0108] Example 7 Synthesis of compound KZ7
[0109] (1) Synthesis of compound KZ7-1
[0110] The preparation method is the same as the synthesis of compound KZ2-3 in step (3) of Example 2, except that methyl 3-bromo-4-hydroxybenzoate is used to replace the raw material KZ2-2, and a white solid is obtained, which is compound KZ7-1.
[0111]
[0112] Compound KZ7-1
[0113] Yield: 68%; 1 H NMR (400MHz, Chloroform-d) δ7.84 (ddd, J=8.4, 2.2, 0.6Hz, 1H), 7.79 (dd, J=2.2, 0.9Hz, 1H), 6.88 (d,J=8.4Hz,1H),3.87(s,3H),1.81(tt,J=8.3,5.3Hz,1H),1.08–0.92(m,2H),0.82–0.66(m,2H).
[0114] (2) Synthesis of compound KZ7-2
[0115] KZ7-1 was dissolved in DMF with 3 equivalents of anhydrous potassium carbonate. 0.5 equivalents of 1,3-dibromopropane were added at room temperature. After stirring for 2 hours at room temperature, 0.7 equivalents of dimethylamine aqueous solution were added, and the mixture was heated to 60°C for a one-pot reaction. After the reaction was completed and cooled to room temperature, ethyl acetate and water were added for extraction three times. The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography to obtain a pale yellow oily substance, which was compound KZ7-2.
[0116]
[0117] Compound KZ7-2
[0118] Yield: 59%; 1 H NMR(500MHz,Chloroform-d)δ7.81(dd,J=8.6,2.2Hz,1H),7.50(d,J=2.2Hz,1H),6.97(s,1H),4.05(t,J=6.1Hz,2H),3.85(s,3H) ,2.65(s,6H),2.13(ddd,J=8.6,7.0,4.3Hz,1H),1.60(p,J=7.9Hz,2H),1.29–1.20(m,2H),0.96–0.89(m,2H),0.71–0.66(m,2H).
[0119] (3) Synthesis of compound KZ7
[0120] The preparation method is the same as that of compound KZ6 in step (2) of Example 6, except that KZ7-2 is used instead of KZ6-1 to obtain a pale yellow solid, compound KZ7.
[0121]
[0122] Compound KZ7
[0123] Yield: 68%; 1 H NMR (400MHz, DMSO-d6) δ10.31(s,1H),8.49(d,J=2.0Hz,1H),8.10(d,J=7.7Hz,1H),7 .83(dd,J=8.3,2.2Hz,1H),7.74(dd,J=8.7,2.1Hz,1H),7.64(d,J=2.2Hz,1H),7.63– 7.57(m,3H),7.46(t,J=7.6Hz,1H),7.19(t,J=7.4Hz,1H),4.44(q,J=7.1Hz,2H),2.3 3–2.15(m,1H),1.32(t,J=7.1Hz,3H),1.08(dt,J=8.7,3.2Hz,2H),0.93–0.80(m,2H). 13 C NMR(101MHz,DMSO-d6)δ164.68,159.43,139.97,136.42,131.20,131.02,126.92,126.54,125.73,123.95,122.12,121.79,12 0.58,120.16,118.58,113.02,110.84,109.18,108.76,65.76,55.00,43.82,36.99,25.54,13.73,9.31,7.99.ESI-HRMS[M+H]+ m / z = 456.2646.
[0124] Example 8: Synthesis of compound KZ8
[0125] (1) Synthesis of compound KZ8-2
[0126] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that 1,4-dibromobutane is used instead of 1,3-dibromopropane to obtain a pale yellow oily substance, compound KZ8-2.
[0127]
[0128] Compound KZ8-2, yield: 60%.
[0129] (2) Synthesis of compound KZ8
[0130] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ8-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ8.
[0131]
[0132] compound KZ8
[0133] Yield: 71%; 1 H NMR (400MHz, DMSO-d6) δ10.09(s,1H),8.48(d,J=2.0Hz,1H),8.08(d,J=7.7Hz,1H),7.86(dd,J=8.5,2.3Hz,1H),7.7 5(dd,J=8.8,2.1Hz,1H),7.59(dd,J=8.6,3.7Hz,2H),7.54(d,J=2.3Hz,1H),7.45(ddd,J=8.3,7.0,1.2Hz,1H),7.19 (t,J=7.5Hz,1H),7.07(d,J=8.7Hz,1H),4.44(q,J=7.1Hz,2H),4.12(t,J=5.7Hz,2H),2.83(s,2H),2.54(s,6H),2.1 9(tt,J=8.5,5.3Hz,1H),1.81(dt,J=10.8,6.9Hz,4H),1.32(t,J=7.1Hz,3H),0.99–0.93(m,2H),0.81–0.76(m,2H). 13C NMR (126MHz, DMSO-d6) δ165.17,159.98,140.45,136.89,131.62,131.50,127.27,127.02,126.20,124.45,122.59,122.25,121.0 6,120.63,119.05,113.49,111.25,109.66,109.23,67.89,57.54,43.52,37.46,26.57,22.22,14.20,9.85,8.41.ESI-HRMS[M+H] + m / z = 470.2802. Example 9: Synthesis of compound KZ9
[0134] (1) Synthesis of compound KZ9-2
[0135] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that 1,5-dibromopentane is used instead of 1,3-dibromopropane to obtain a pale yellow oily substance, which is compound KZ9-2.
[0136]
[0137] Compound KZ9-2, yield: 55%.
[0138] (2) Synthesis of compound KZ9
[0139] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ9-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ9.
[0140]
[0141] Compound KZ9
[0142] Yield: 69%; 1H NMR (400MHz, DMSO-d6) δ10.07(s,1H),8.48(s,1H),8.08(d,J=7.8Hz,1H),7.84(d,J=8.6Hz,1H),7.74(d,J=8. 8Hz,1H),7.60(d,J=3.0Hz,1H),7.58(d,J=3.6Hz,1H),7.54–7.49(m,1H),7.45(t,J=7.7Hz,1H),7.19(t,J=7. 4Hz,1H),7.06(d,J=8.6Hz,1H),4.44(q,J=7.1Hz,2H),4.09(t,J=6.5Hz,2H),2.27(d,J=6.8Hz,2H),2.17(s,7 H),1.80(t,J=6.8Hz,2H),1.54–1.43(m,4H),1.32(t,J=7.1Hz,3H),0.95(d,J=8.2Hz,2H),0.81–0.70(m,2H). 13 C NMR(126MHz,DMSO-d6)δ164.74,159.62,139.98,136.41,131.15,131.05,126.70,126.51,125.72,123.86,122.13,121.79,120.57,1 20.17,118.58,113.00,110.77,109.18,108.76,67.88,58.88,44.97,37.00,28.58,26.52,23.44,13.73,9.32,7.99.ESI-HRMS[M+H] + m / z = 484.2959.
[0143] Example 10 Synthesis of compound KZ10
[0144] (1) Synthesis of compound KZ10-2
[0145] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that tetrahydropyrrole is used instead of dimethylamine. After purification, a pale yellow oily substance is obtained, which is compound KZ10-2.
[0146]
[0147] Compound KZ10-2
[0148] Yield: 50%; 1H NMR(500MHz,Chloroform-d)δ7.81(dd,J=8.6,2.2Hz,1H),7.50(d,J=2.2Hz,1H),6.80(d,J=8.5Hz,1H),4.05(t,J=6.0Hz,2H),3.85(s,3H),2.18–2.09 (m,4H),2.02(qd,J=7.7,7.2,4.3Hz,2H),1.89(dq,J=11.9,6.2Hz,2H),1.6 1(q,J=8.1Hz,2H),1.29–1.21(m,1H),0.98–0.90(m,2H),0.72–0.65(m,2H).
[0149] (2) Synthesis of compound KZ10
[0150] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ10-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ10.
[0151]
[0152] Compound KZ10
[0153] Yield: 56%; 1 H NMR (500MHz, DMSO-d6) δ10.06(s,1H),8.47(d,J=2.0Hz,1H),8.08(d,J=7.7Hz,1H),7.88(dd,J=8.6,2.3Hz,1H),7.74( dd,J=8.8,2.1Hz,1H),7.59(dd,J=8.6,3.3Hz,2H),7.55(d,J=2.2Hz,1H),7.45(t,J=7.7Hz,1H),7.19(t,J=7.4Hz,1H) ,7.09(d,J=8.5Hz,1H),4.44(q,J=7.1Hz,2H),4.20(t,J=6.0Hz,2H),3.61(s,2H),3.37(t,J=7.9Hz,2H),3.07(s,2H), 2.20(td,J=8.3,4.3Hz,3H),2.04(s,2H),1.90(s,2H),1.33(t,J=7.1Hz,3H),1.03–0.91(m,2H),0.79(q,J=5.3Hz,2H). 13C NMR(126MHz,DMSO-d6)δ165.07,159.65,140.45,136.91,131.70,131.43,127.61,127.03,126.22,124.43,122.26,121.06,1 20.63,119.07,113.51,111.35,109.67,109.25,65.56,53.92,51.96,37.47,25.94,23.06,14.20,9.75,8.50.ESI-HRMS[M+H] + m / z = 482.2802. Example 11: Synthesis of compound KZ11
[0154] (1) Synthesis of compound KZ11-2
[0155] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that tetrahydropyrrole is used instead of dimethylamine and 1,4-dibromobutane is used instead of 1,3-dibromopropane to obtain a pale yellow oily substance, which is compound KZ11-2.
[0156]
[0157] Compound KZ11-2, yield: 59%.
[0158] (2) Synthesis of compound KZ11
[0159] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ11-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ11.
[0160]
[0161] Compound KZ11
[0162] Yield: 65%; 1H NMR (400MHz, DMSO-d6) δ10.08(s,1H),8.48(s,1H),8.08(d,J=7.8Hz,1H),7.86(d,J=8.6Hz,1H),7.7 4(d,J=8.8Hz,1H),7.59(dd,J=8.7,3.2Hz,2H),7.54(s,1H),7.45(t,J=7.7Hz,1H),7.19(t,J=7.4Hz ,1H),7.08(d,J=8.6Hz,1H),4.44(q,J=7.1Hz,2H),4.13(d,J=5.8Hz,2H),3.09(s,6H),2.19(p,J=7. 0Hz, 1H), 1.87 (d, J = 20.2Hz, 8H), 1.32 (t, J = 7.1Hz, 3H), 0.97 (d, J = 8.0Hz, 2H), 0.79 (d, J = 5.3Hz, 2H). 13 C NMR(126MHz,DMSO-d6)δ165.14,159.94,140.45,136.90,131.59,131.47,127.31,127.02,126.21,124.43,122.58,122.26,121.06,1 20.63,119.06,113.49,111.25,109.66,109.24,67.77,57.14,54.45,53.68,37.46,26.50,23.16,14.20,9.84,8.43.ESI-HRMS[M+H] + m / z = 496.2959.
[0163] Example 12 Synthesis of compound KZ12
[0164] (1) Synthesis of compound KZ12-2
[0165] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that tetrahydropyrrole is used instead of dimethylamine and 1,5-dibromopentane is used instead of 1,3-dibromopropane to obtain a pale yellow oily substance, which is compound KZ12-2.
[0166]
[0167] Compound KZ12-2, yield: 51%.
[0168] (2) Synthesis of compound KZ12
[0169] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ12-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ12.
[0170]
[0171] Compound KZ12
[0172] Yield: 67%; 1 H NMR (500MHz, DMSO-d6) δ10.08(s,1H),8.48(d,J=1.9Hz,1H),8.08(d,J=7.6Hz,1H),7.84(dd,J=8.5,2.3Hz,1H),7.74(dd,J=8.8 ,2.1Hz,1H),7.60(d,J=3.2Hz,1H),7.58(d,J=3.6Hz,1H),7.51(d,J=2.3Hz,1H),7.45(t,J=7.6Hz,1H),7.19(t,J=7.4Hz,1H),7. 06(d,J=8.6Hz,1H),4.44(q,J=7.1Hz,2H),4.09(t,J=6.3Hz,2H),2.44(q,J=7.2,6.5Hz,6H),2.18(tt,J=8.4,5.3Hz,1H),1.80( p,J=6.6Hz,2H),1.67(h,J=3.2Hz,4H),1.52(dt,J=8.9,5.2Hz,4H),1.32(t,J=7.1Hz,3H),1.00–0.90(m,2H),0.80–0.72(m,2H). 13 C NMR (126MHz, DMSO-d6) δ165.20,160.09,140.44,136.87,131.61,131.52,127.16,126.98,126.19,124.32,122.60,122.26,121.03,120. 64,119.04,113.46,111.22,109.64,109.22,68.32,55.99,54.05,37.46,29.08,28.42,24.08,23.52,14.20,9.79,8.45.ESI-HRMS[M+H] + m / z = 510.3115.
[0173] Example 13 Synthesis of compound KZ13
[0174] (1) Synthesis of compound KZ13-2
[0175] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that piperidine is used instead of dimethylamine. After purification, a pale yellow oily substance is obtained, which is compound KZ13-2.
[0176]
[0177] Compound KZ13-2
[0178] Yield: 49%; 1 H NMR(500MHz,Chloroform-d)δ7.81(dd,J=8.5,2.2Hz,1H),7.51(d,J=2.2Hz,1H),6.81(d,J=8.6Hz,1H),4.04(t,J=6.3Hz,2H),3.86( s,3H),2.54–2.33(m,6H),1.86(p,J=6.6Hz,2H),1.62(q,J=5.6,5.1Hz,6H),1.28–1.24(m,1H),1.00–0.90(m,2H),0.72–0.66(m,2H).
[0179] (2) Synthesis of compound KZ13
[0180] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ13-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ13.
[0181]
[0182] Compound KZ13
[0183] Yield: 66%; 1H NMR (500MHz, DMSO-d6) δ10.10(s,1H),8.48(d,J=2.0Hz,1H),8.09(d,J=7.7Hz,1H),7.87(dd,J=8.5,2.3Hz,1H),7.74(d d,J=8.7,2.1Hz,1H),7.60(dd,J=8.6,2.5Hz,2H),7.54(d,J=2.3Hz,1H),7.46(t,J=7.7Hz,1H),7.19(t,J=7.4Hz,1H),7. 09(d,J=8.6Hz,1H),4.44(q,J=7.1Hz,2H),4.18(t,J=5.9Hz,2H),3.33(s,2H),3.25(s,2H),2.93(s,2H),2.21(dq,J=13. 1,7.4,6.2Hz,3H),1.75(d,J=80.7Hz,5H),1.41(s,1H),1.32(t,J=7.1Hz,3H),1.03–0.95(m,2H),0.80(t,J=5.6Hz,2H). 13 C NMR (126MHz, DMSO-d6) δ164.61,159.20,139.98,136.45,131.23,130.97,127.13,126.56,125.76,123.97,122.11,121.80,120.6 0,120.16,118.61,113.05,110.89,109.20,108.78,65.32,54.92,53.63,52.36,37.00,21.35,13.73,9.28,8.04.ESI-HRMS[M+H] + m / z = 496.2959.
[0184] Example 14 Synthesis of compound KZ14
[0185] (1) Synthesis of compound KZ14-2
[0186] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that piperidine is used instead of dimethylamine and 1,4-dibromobutane is used instead of 1,3-dibromopropane to obtain a pale yellow oily substance, which is compound KZ14-2.
[0187]
[0188] Compound KZ14-2, yield: 59%.
[0189] (2) Synthesis of compound KZ14
[0190] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ14-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ14.
[0191]
[0192] Compound KZ14
[0193] Yield: 54%; 1 H NMR (500MHz, DMSO-d6) δ10.08(s,1H),8.47(d,J=2.0Hz,1H),8.08(d,J=7.7Hz,1H),7.87(dd,J=8.4,2.3Hz,1H),7.74(dd ,J=8.9,2.0Hz,1H),7.60(dd,J=8.5,3.7Hz,2H),7.54(d,J=2.3Hz,1H),7.45(t,J=7.6Hz,1H),7.19(t,J=7.5Hz,1H),7.0 8(d,J=8.6Hz,1H),4.44(q,J=7.1Hz,2H),4.15(d,J=5.7Hz,2H),3.45(d,J=9.0Hz,2H),3.13(s,2H),2.87(d,J=13.2Hz,2 H),2.19(td,J=8.5,4.3Hz,1H),1.86–1.64(m,10H),1.33(d,J=7.1Hz,3H),0.97(d,J=8.2Hz,2H),0.80(d,J=4.4Hz,2H). 13 C NMR (126MHz, DMSO-d6) δ164.64,159.42,139.99,136.44,131.11,130.98,126.88,126.56,125.75,123.92,122.11,121.79,120.59,120. 15,118.60,113.03,110.78,109.20,108.77,67.23,55.62,52.13,36.99,34.72,34.24,22.60,21.31,13.73,9.34,8.02.ESI-HRMS[M+H] + m / z = 510.3115.
[0194] Example 15 Synthesis of compound KZ15
[0195] (1) Synthesis of compound KZ15-2
[0196] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that piperidine is used instead of dimethylamine and 1,5-dibromopentane is used instead of 1,3-dibromopropane to obtain a pale yellow oily substance, which is compound KZ15-2.
[0197]
[0198] Compound KZ15-2, yield: 56%.
[0199] (2) Synthesis of compound KZ15
[0200] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ15-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ15.
[0201]
[0202] Compound KZ15
[0203] Yield: 47%; 1 H NMR (500MHz, DMSO-d6) δ10.08(s,1H),8.47(d,J=2.1Hz,1H),8.08(d,J=7.7Hz,1H),7.86(dd,J=8.5,2.3Hz,1H),7.74(dd,J=8.8,2.1Hz,1 H),7.60(d,J=3.0Hz,1H),7.59(d,J=3.6Hz,1H),7.53(d,J=2.3Hz,1H),7.45(t,J=7.7Hz,1H),7.19(t,J=7.4Hz,1H),7.08(d,J=8.6Hz,1H ),4.44(q,J=7.1Hz,2H),4.11(q,J=4.8,3.2Hz,2H),3.43(s,2H),3.05(t,J=8.5Hz,2H),2.85(s,2H),2.18(td,J=8.5,4.3Hz,1H),1.83(d t,J=12.9,6.6Hz,4H),1.77–1.68(m,4H),1.63(s,2H),1.51(q,J=7.5Hz,2H),1.32(t,J=7.1Hz,3H),1.00–0.92(m,2H),0.81–0.77(m,2H). 13C NMR (126MHz, DMSO-d6) δ165.14,159.99,140.45,136.90,131.59,131.46,127.25,127.01,126.22,124.33,122.58,122.26,121.05,120. 62,119.06,113.49,111.24,109.67,109.24,67.95,56.21,52.57,37.46,28.67,23.50,23.10,21.81,14.19,9.78,8.49.ESI-HRMS[M+H] + m / z = 524.3272.
[0204] Example 16 Synthesis of compound KZ16
[0205] (1) Synthesis of compound KZ16-2
[0206] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that morpholine is used instead of dimethylamine. After purification, a pale yellow oily substance is obtained, which is compound KZ16-2.
[0207]
[0208] Compound KZ16-2
[0209] Yield: 53%; 1 H NMR(500MHz,Chloroform-d)δ7.82(dd,J=8.5,2.2Hz,1H),7.52(d,J=2.2Hz,1H),6.84(d,J=8.6Hz,1H),4.12(t,J=6.2Hz,2H),3.86(s,3H),3.72(t ,J=4.7Hz,4H),2.57(t,J=7.3Hz,2H),2.48(t,J=4.6Hz,4H),2.14(tt,J= 8.6,5.4Hz,1H),2.06–2.00(m,2H),0.97–0.92(m,2H),0.72–0.66(m,2H).
[0210] (2) Synthesis of compound KZ16
[0211] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ16-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ16.
[0212]
[0213] Compound KZ16
[0214] Yield: 71%; 1 H NMR (400MHz, DMSO-d6) δ10.08(s,1H),8.48(d,J=1.7Hz,1H),8.08(d,J=7.7Hz,1H),7.85(dd,J=8.5,2.1Hz,1H),7.74 (dd,J=8.8,1.8Hz,1H),7.63–7.55(m,2H),7.52(d,J=2.0Hz,1H),7.45(t,J=7.6Hz,1H),7.19(t,J=7.4Hz,1H),7.07(d ,J=8.6Hz,1H),4.44(q,J=7.0Hz,2H),4.13(t,J=6.1Hz,2H),3.72–3.52(m,4H),2.50–2.47(m,2H),2.40(s,4H),2.18 (ddd,J=13.8,8.5,5.4Hz,1H),1.95(p,J=6.4Hz,2H),1.32(t,J=7.1Hz,3H),1.02–0.90(m,2H),0.77(q,J=5.8Hz,2H). 13 C NMR(101MHz,DMSO-d6)δ165.19,160.05,140.45,136.89,131.66,131.52,127.26,127.01,126.19,124.42,122.60,122.27,12 1.04,120.64,119.05,113.47,111.31,109.65,109.23,66.65,55.37,53.85,37.47,26.32,14.20,9.83,8.41.ESI-HRMS[M+H] + m / z = 498.2751. Example 17: Synthesis of compound KZ17
[0215] (1) Synthesis of compound KZ17-2
[0216] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that morpholine is used instead of dimethylamine and 1,4-dibromobutane is used instead of 1,3-dibromopropane. After column chromatography purification, a pale yellow oily substance, compound KZ17-2, is obtained.
[0217]
[0218] Compound KZ17-2, yield: 52%.
[0219] (2) Synthesis of compound KZ17
[0220] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ17-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ17.
[0221]
[0222] Compound KZ17
[0223] Yield: 61%; 1 H NMR (400MHz, DMSO-d6) δ10.07(s,1H),8.48(d,J=2.0Hz,1H),8.08(d,J=7.7Hz,1H),7.85(dd,J=8.6,2.3Hz,1H),7.74(dd,J=8.8 ,2.1Hz,1H),7.60(d,J=2.8Hz,1H),7.58(d,J=3.3Hz,1H),7.52(d,J=2.3Hz,1H),7.45(ddd,J=8.3,7.1,1.2Hz,1H),7.19(t,J=7 .5Hz,1H),7.07(d,J=8.6Hz,1H),4.44(q,J=7.0Hz,2H),4.12(t,J=6.3Hz,2H),3.56(t,J=4.6Hz,4H),2.34(d,J=6.9Hz,6H),2.1 8(tt,J=8.5,5.3Hz,1H),1.85–1.77(m,2H),1.65(q,J=7.4Hz,2H),1.32(t,J=7.1Hz,3H),1.01–0.92(m,2H),0.81–0.74(m,2H). 13 C NMR(101MHz,DMSO-d6)δ165.20,160.07,140.45,136.88,131.58,131.52,127.15,126.99,126.19,124.36,122.60,122.27,121.05,1 20.64,119.05,113.48,111.21,109.64,109.23,68.25,66.68,58.26,53.78,37.47,27.08,22.89,14.20,9.82,8.43.ESI-HRMS[M+H] + m / z = 512.2908.
[0224] Example 18 Synthesis of compound KZ18
[0225] (1) Synthesis of compound KZ18-2
[0226] The preparation method is the same as the synthesis of compound KZ7-2 in step (2) of Example 7, except that morpholine is used instead of dimethylamine and 1,5-dibromopentane is used instead of 1,3-dibromopropane. After purification by column chromatography, a pale yellow oily substance is obtained, which is compound KZ18-2.
[0227]
[0228] Compound KZ18-2, yield: 53%.
[0229] (2) Synthesis of compound KZ18
[0230] The preparation method is the same as the synthesis of compound KZ6 in step (2) of Example 6, except that KZ18-2 is used instead of KZ6-1 to obtain a pale yellow solid, which is compound KZ18.
[0231]
[0232] Compound KZ18
[0233] Yield: 64%; 1 H NMR (400MHz, DMSO-d6) δ10.08(s,1H),8.48(s,1H),8.08(d,J=7.7Hz,1H),7.84(d,J=8.5Hz,1H),7.74(d,J= 8.5Hz,1H),7.60(s,1H),7.58(d,J=2.5Hz,1H),7.52(s,1H),7.45(t,J=7.6Hz,1H),7.19(t,J=7.4Hz,1H),7 .06(d,J=8.6Hz,1H),4.44(q,J=6.8Hz,2H),4.09(t,J=6.1Hz,2H),3.56(s,4H),2.34(s,6H),2.21–2.13(m, 1H), 1.79 (d, J = 6.3Hz, 2H), 1.50 (s, 4H), 1.32 (t, J = 7.0Hz, 3H), 0.95 (d, J = 8.1Hz, 2H), 0.77 (d, J = 4.3Hz, 2H). 13C NMR (126MHz, DMSO-d6) δ164.72,159.62,139.97,136.41,131.13,131.05,126.69,126.51,125.71,123.85,122.13,121.79,120.56,120. 16,118.57,112.99,110.75,109.16,108.75,67.85,66.18,58.14,53.34,36.99,34.24,28.59,23.49,13.72,9.32,7.97.ESI-HRMS[M+H] + m / z = 526.3064.
[0234] Example 19 Synthesis of compound KZ19
[0235] (1) Synthesis of compound KZ19-1
[0236] 3-Nitro-9H-carbazole and 0.1 equivalents of 4-dimethylaminopyridine (DMAP) were dissolved in dichloromethane and cooled in an ice bath. One equivalent of ditert-butyl dicarbonate was added dropwise. After reacting in an ice bath for 10 minutes, the mixture was transferred to room temperature and the reaction continued for 1 hour. After the reaction was completed, a large amount of ice water was added, and a large amount of solid precipitated. After filtration and drying, a yellow solid was obtained, which was compound KZ19-1, and no purification was required.
[0237]
[0238] Compound KZ19-1
[0239] Yield: 90%; 1 H NMR(500MHz,Chloroform-d)δ8.87(d,J=2.3Hz,1H),8.45(d,J=9.2Hz,1H),8.36(dd,J=9.2,2.3Hz,1H ),8.31(d,J=8.4Hz,1H),8.07(d,J=7.7Hz,1H),7.61–7.55(m,1H),7.45(t,J=7.5Hz,1H),1.79(s,9H).
[0240] (2) Synthesis of compound KZ19-2
[0241] The preparation method is the same as the synthesis of compound KZ2-2 in step (2) of Example 2, except that KZ19-1 is used instead of KZ-1. After purification by column chromatography, a pale yellow solid is obtained, which is compound KZ19-2.
[0242]
[0243] Compound KZ19-2
[0244] Yield: 88%; 1 H NMR(400MHz,Chloroform-d)δ8.26(d,J=8.4Hz,1H),8.09(d,J=8.7Hz,1H),7.87(dd,J=7.5,1.1Hz, 1H),7.43(ddd,J=8.5,7.2,1.3Hz,1H),7.33–7.27(m,2H),6.89(dd,J=8.8,2.4Hz,1H),1.74(s,9H).
[0245] (3) Synthesis of compound KZ19
[0246] The preparation method is the same as in Example 1, except that KZ19-2 is used instead of 3-amino-9-ethylcarbazole. After purification by column chromatography, a yellow solid is obtained, which is compound KZ19.
[0247]
[0248] Compound KZ19
[0249] Yield: 83%; 1 H NMR(400MHz,Chloroform-d)δ8.41(d,J=2.0Hz,1H),8.38(s,1H),8.28(d,J=5.0Hz,1H),8.26(d,J=4.6Hz,1H),8.05(dd,J=8.3,2.1Hz,1H), 7.91(d,J=7.7Hz,1H),7.64(d,J=8.3Hz,1H),7.51(dd,J=9.2,2.3Hz,1H),7.47(ddd,J=8.4,7.3,1.3Hz,1H),7.37–7.30(m,1H),1.77(s,9H). 13 C NMR(126MHz,Chloroform-d)δ162.60,151.05,147.89,139.07,136.01,134.75,132.67,132.55,131.79, 130.72,127.73,126.50,125.40,124.33,123.28,120.18,119.99,116.87,116.46,112.14,84.37,28.53.
[0250] Example 20 Synthesis of compound KZ20
[0251] Compound KZ19 was dissolved in dichloromethane / trifluoroacetic acid (volume ratio: 4:1), reacted at room temperature for 1 hour, and the reaction solution was evaporated to dryness. The solution was extracted three times with dichloromethane / saturated sodium bicarbonate solution, and the organic phases were combined. The mixture was dried with anhydrous magnesium chloride, filtered through diatomaceous earth, evaporated to dryness, and purified by column chromatography to obtain a yellow solid, which was compound KZ20.
[0252]
[0253] Compound KZ20
[0254] Yield: 90%; 1 H NMR (400MHz, DMSO-d6) δ11.26(s,1H),10.57(s,1H),8.70(d,J=2.1Hz,1H),8.49(d,J=2.0Hz,1H),8.32(dd,J=8.4,2.2Hz,1H),8.06(d,J=7.8 Hz,1H),7.99(d,J=8.4Hz,1H),7.70(dd,J=8.7,2.1Hz,1H),7.50(d,J=2.1Hz,1H),7.48(s,1H),7.39(t,J=7.6Hz,1H),7.16(t,J=7.4Hz,1H). 13 C NMR(101MHz,DMSO-d6)δ162.04,147.39,140.33,136.92,135.21,132.75,131.96,130.06, 127.83,125.72,124.75,122.34,122.13,120.16,120.04,118.55,112.75,111.12,110.81.
[0255] Test Example 1
[0256] Four tumor cell lines, RKO (human colon adenocarcinoma cells), U2OS (human osteosarcoma cells), HCT116 (human colon cancer cells), and DU145 (human prostate cancer cells), were used to perform in vitro cytotoxicity assays using the CCK8 method.
[0257] Test method: Different concentrations of N-(9H-carbazole-3-yl)benzamide derivatives were added to cells in the logarithmic growth phase. After 72 hours of treatment, the absorbance was measured. Specific operating procedures:
[0258] (1) Cell grafting: Seed cells in the logarithmic growth phase into 96-well plates (approximately 3000 cells / well), 100 μL per well, and then incubate in a 37°C cell culture incubator containing 5% CO2.
[0259] (2) Drug administration: After culturing for 24 hours, discard the old culture medium and add 100 μL of the compound diluted with culture medium (RPMI-1640 medium for RKO and HCT-116, and DMEM medium for DU145 and U2OS) to each well; set up the untreated group as the control group and continue to culture in the cell culture incubator.
[0260] (3) Detection: After 72 h of cell culture, 10 μL of CCK-8 reagent was added to each well, and the cells were incubated for another 3 h. Afterward, the absorbance at 450 nm was measured using a microplate reader. Three replicates were set up for each drug concentration, including the control group, and the average absorbance was calculated. Cell proliferation inhibition rate = (OD 对照组 -OD 给药组 ) / (OD 对照组 -OD 空白孔 The IC50 was calculated by fitting the cell proliferation inhibition rate to the drug concentration using GraphPadprism software, resulting in an IC50 value of 100%. 50 value.
[0261] Calculate the concentration of the compound that inhibits cell growth by 50%, expressed as IC50. 50 The values represent the results, with DTHIB, a direct selective inhibitor of heat shock factor 1, used as a positive control. The results are shown in Table 1.
[0262] Table 1
[0263]
[0264]
[0265] As shown in Table 1 above, the N-(9H-carbazole-3-yl)benzamide derivative provided by the present invention has a strong inhibitory effect on all four cell lines in vitro, and its effect is better than that of the existing direct selective inhibitor of heat shock factor 1, DTHIB. Therefore, the N-(9H-carbazole-3-yl)benzamide derivative described in the present invention can be used to prepare anticancer drugs.
[0266] Test Example 2
[0267] Representative compounds were selected, and their inhibitory function on HSF1 was evaluated using Western blot technology. The index examined was the effect of different drug concentrations on the protein levels of HSF1 and its downstream proteins HSP90, HSP70 and Akt.
[0268] Test method: Representative compounds at different concentrations were added to cells in the logarithmic growth phase. After 72 hours of treatment, changes in protein levels were detected by Western blot. Specific procedures:
[0269] (1) Sample preparation: Take RKO cells in the logarithmic growth phase, and divide them into approximately 5 × 10⁶ cells per well. 5 Cells were seeded at a density of 1000 cells / well in six-well plates and cultured overnight in a cell culture incubator. Subsequently, different concentrations of compounds (KZ1 and KZ13) were added to RPMI-1640 medium, and the cells were cultured for 48 or 72 hours. After culture, the medium was removed, and the cells were washed twice with 1×PBS solution before being transferred to 1.5 mL EP tubes. The cells were centrifuged at 1000 rpm for 5 minutes at room temperature, and the supernatant was removed. Approximately 50 μL of RIPA lysis buffer and a protease inhibitor were added to the cell pellet, and the mixture was incubated on ice for 30 minutes. Next, the cells were centrifuged at 12000 rpm for 15 minutes at 4°C, and the supernatant was transferred to a new EP tube. A portion of the supernatant was used for protein concentration determination using the BCA method, and the remaining supernatant was denatured by adding 5× loading buffer and heating at 95°C for 10 minutes.
[0270] (2) Gel electrophoresis: Prepare a 10% separating gel and a 5% stacking gel; calculate the appropriate loading amount and load the sample into the gel wells. In 1×SDS electrophoresis buffer, first set 80V and run until the sample concentration is complete, then set 120V and continue running for about 1 hour. Take the separating gel.
[0271] (3) Transfer: Cut a PVDF membrane of the same size as the separating gel (soak it in anhydrous methanol for 1 min before use) and transfer filter paper. Assemble the wet transfer device in the order of negative electrode, fiber pad, transfer filter paper, gel, PVDF membrane, transfer filter paper, fiber pad, positive electrode, and transfer the membrane on ice for 2 h at a constant current of 300 mA in 1×Trans wet transfer buffer.
[0272] (4) Blocking: Immerse the protein-converted PVDF membrane in 1×TBST buffer for 5 seconds, remove it and immerse it in 5% BSA, and block it in a shaker at room temperature for 1 hour.
[0273] (5) Primary antibody incubation: Query the protein molecular weight, cut out the corresponding band, transfer it to the primary antibody dilution solution, and incubate overnight at 4°C and 30 rpm.
[0274] (6) Washing: Remove the membrane and immerse it in 1×TBST solution. Wash at room temperature and 60 rpm for 5 min. Repeat 4 times.
[0275] (7) Secondary antibody incubation: Take out the membrane and carefully immerse it in the secondary antibody dilution solution. Incubate at room temperature and 30 rpm for 1 h.
[0276] (8) Washing: Remove the membrane and immerse it in 1×TBST solution. Wash at room temperature and 60 rpm for 5 min. Repeat 4 times.
[0277] (9) Development: Place the membrane in a Tanon 4600 fully automated chemiluminescence analyzer and evenly drop chemiluminescent solution onto it for development.
[0278] Figure 1 This is a schematic diagram illustrating the inhibition of HSF1 activity by a compound. Figure 1 As shown, the N-(9H-carbazole-3-yl)benzamide derivative provided by the present invention can significantly inhibit the activity of HSF1, manifested by a significant reduction in the levels of HSF1 and its downstream proteins HSP90, HSP70 and Akt protein.
[0279] The above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. For those skilled in the art, other variations or modifications can be made based on the above description and ideas. It is neither necessary nor possible to exhaustively describe all implementation methods here. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the scope of protection of the claims of the present invention.
Claims
1. An N-(9H-carbazole-3-yl)benzamide derivative, characterized in that, It has the structure shown in equation (I): Among them, R1 is selected from halogen, C 1~8 Alkoxy; the C 1~8 The alkoxy group is either unsubstituted or substituted with one or more -NR5R6 groups; R2 is selected from nitro, C 3~8 cycloalkyl, C 3~8 Heterocyclic groups; R3 is selected from hydrogen, C 1~8 Alkyl, C 1~8 alkoxycarbonyl; R4 is selected from C 3~8 cycloalkyl, C 3~8 Heterocyclic group, C 2~8 alkenyl, C 1~8 Alkyl; the C 2~8 alkenyl, C 1~8 Alkyl groups that are unsubstituted or via one or more amino groups, C 3~12 Cycloalkylamino, aryl, heteroaryl, C 3~8 Substitution of heterocyclic groups; R5 and R6 are each independently selected from hydrogen and C. 1~8 Alkyl groups; or R5, R6, and the nitrogen atom attached to them to form C 3~8 Heterocyclic group.
2. The N-(9H-carbazole-3-yl)benzamide derivative according to claim 1, characterized in that, R1 is selected from fluorine, chlorine, bromine, C 2~6 Alkoxy; the C 2~6 The alkoxy group is either unsubstituted or substituted with one or more -NR5R6 groups; R2 is selected from nitro, C 3~6 cycloalkyl, C 3~6 Heterocyclic groups; R3 is selected from hydrogen, C 1~4 Alkyl, C 1~4 alkoxycarbonyl; R4 is selected from C 4~6 cycloalkyl, C 4~6 Heterocyclic group, C 2~6 alkenyl, C 1~4 Alkyl; the C 2~6 alkenyl, C 1~4 Alkyl groups that are unsubstituted or via one or more amino groups, C 6~10 Cycloalkylamino, C 5~6 Aryl, C 5~6 heteroaryl, C 4~6 Substitution of heterocyclic groups; R5 and R6 are each independently selected from hydrogen and C. 1~4 Alkyl groups; or R5, R6, and the nitrogen atom attached to them to form C 4~6 Heterocyclic group.
3. The N-(9H-carbazole-3-yl)benzamide derivative according to claim 2, characterized in that, R1 is selected from chlorine, C 3~5 Alkoxy; the C 3~5 The alkoxy group is either unsubstituted or substituted with one or more -NR5R6 groups; R2 is selected from nitro, C 3~6 cycloalkyl, C 3~6 Heterocyclic groups; R3 is selected from hydrogen, C 1~4 Alkyl, C 1~4 alkoxycarbonyl; R4 is selected from pyranyl, tetrahydropyrrolyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, piperazine, dioxane, C 2~4 alkenyl, C 1~3 Alkyl; the C 2~4 alkenyl, C 1~3 The alkyl group is either unsubstituted or substituted with one or more phenyl, pyranyl, tetrahydropyrrolyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, piperazine, or adamantylamino groups; R5 and R6 are each independently selected from C 1~3 Alkyl groups; or nitrogen atoms attached to R5 and R6 to form pyranyl, tetrahydropyrroleyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, piperazineyl, or dioxaneyl.
4. The N-(9H-carbazole-3-yl)benzamide derivative according to claim 3, characterized in that, R1 is selected from chloro, styrylformamido, 2-morpholinoacetamido, 2-adamantaneaminoacetamido, 3-dimethylaminopropoxy, 4-(dimethylamino)butoxy, 5-(dimethylamino)pentoxy, 3-(pyrrolidone-1-yl)propoxy, 4-(pyrrolidone-1-yl)butoxy, 5-(pyrrolidone-1-yl)pentoxy, 3-(piperidin-1-yl)propoxy, 4-(piperidin-1-yl)butoxy, 5-(piperidin-1-yl)pentoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, and 5-morpholinopentoxy. R2 is selected from nitro or cyclopropyl; R3 is selected from hydrogen, ethyl, or tert-butoxycarbonyl.
5. The N-(9H-carbazole-3-yl)benzamide derivative according to claim 4, characterized in that, The N-(9H-carbazole-3-yl)benzamide derivative has any of the following structures:
6. The use of the N-(9H-carbazole-3-yl)benzamide derivative according to any one of claims 1 to 5 in the preparation of heat shock protein inhibitors.
7. The use of the N-(9H-carbazole-3-yl)benzamide derivative according to any one of claims 1 to 5 in the preparation of medicaments for the prevention and / or treatment of heat shock factor 1-mediated diseases.
8. The application according to claim 7, characterized in that, The relevant diseases are one or more of the following: colon adenocarcinoma, osteosarcoma, colon cancer, and prostate cancer.
9. The application according to claim 7, characterized in that, The heat shock factor 1 induces related diseases by mediating heat shock protein HSP90 or heat shock protein HSP70.
10. A heat shock protein inhibitor, characterized in that, It comprises the N-(9H-carbazole-3-yl)benzamide derivative as described in any one of claims 1 to 5; and pharmaceutically acceptable excipients.
